BeyondSpring is trading at $0.67 (-5.69%) after its August 14, 2026, second-quarter update reported cash, equivalents, and short-term investments falling to $6.5 million from $12.6 million at year-end 2025, raising financing and potential dilution concerns.
- The planned 442-patient DUBLIN-4 Phase 3 trial faces funding concerns.
- Shares fell 15.21% on August 17, 2026, following the update; a 1.25% Nasdaq decline may have added pressure.
- No separate August 18, 2026, company announcement was identified.